Validation of urinary HE4 as a biomarker for ovarian cancer. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full text component.
The biopharmaceutical industry is finally coming of age and we are seeing more biologic therapies reaching the clinic to treat a variety of ailments. These range from rare, previously undruggable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results